Navigation Links
AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Date:11/13/2008

reciation and

amortization:

Property, plant and

equipment 433 426 1,199 1,183

Intangible assets 839 1,024 2,555 3,014

-------------------------------------------------------------------------

23,415 20,422 77,303 54,686

-------------------------------------------------------------------------

Loss from operations (12,386) (9,379) (46,069) (22,858)

Other income (expenses)

Interest income 149 494 737 1,369

Interest expense - (15) (68) (68)

Foreign exchange (loss)

gain (1,324) (170) 429 (766)

Loss on disposal of

long-lived assets held

for sale (90) - (125) -

-------------------------------------------------------------------------

(1,265) 309 973 535

-------------------------------------------------------------------------

Loss before income taxes (13,651) (9,070) (45,096) (22,323)

Income tax (expense)

recovery (228) 1,012 (228) 4,287

-------------------------------------------------------------------------

Net loss from continuing

operations (13,879) (8,058) (45,324) (18,036)

Net loss from

discontinued operations - (646) - (624)

-------------------------------------------------------------------------

Net loss for the period (13,879) (8,704) (45,324) (18,660)

-------------------------------------------------------------------------

----------------------------------------------------------------
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
2. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
4. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
10. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
11. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Pfanstiehl has announced the launch of ... the USA under ICH ... for playing a key role in protein glycosylation.  ... that media supplementation with mannose can improve overall ... to Dr. Christopher Wilcox , VP, Business ...
(Date:10/1/2014)... (PRWEB) September 30, 2014 In ... cost-effective tools to address sales, training and consumer ... has developed innovative mobile applications to turn their ... the agency’s latest customized mobile app creations, are ... . , In partnership with Toyota, StudioPMG created ...
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... This news release is available in German . ... photonic crystal around several quantum dots in a semiconductor layer. ... a consequence of atomic processes. If a short laser pulse ... modified and the quantum dot experiences a change in the ... slow down the emission of light by the dot. As ...
Breaking Biology Technology:Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Ultrafast remote switching of light emission 2
... Boston Scientific Corporation (NYSE: BSX ) today ... and Drug Administration (FDA) to market its TAXUS(R) Liberte ... deliverable, next-generation drug-eluting stent (DES) specifically designed for treating ... in vessels as small as 2.25 mm in diameter ...
... Network Sciences, Inc. (GNS) today announced that it ... University of California San Francisco Cancer ... drug development across several therapeutic areas. This collaboration ... of UCSF with the computational expertise and supercomputer-driven ...
... Cell Institute (RSCI) today announced its 2009 Science Advisory Board. Once ... world-leader and has a world-first to his credit. , ... Dallas, Texas ... http://www.RepairStemCells.org , a Dallas, Texas-based stem cell global public affairs organization founded ...
Cached Biology Technology:FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 2FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 3FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System 4Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results 2RSCI Announces World-Leading Stem Cell Science Advisory Board 2RSCI Announces World-Leading Stem Cell Science Advisory Board 3
(Date:9/30/2014)... want your doctor to know what goes wrong with your ... idea to know what "normal" actually is. That,s where a ... the FASEB Journal comes in. In ... key set of molecules that can help scientists "see" which ... What,s more, they found never-before-detected gene activity and that men ...
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/30/2014)... of The Economist,s prestigious Innovation awards 2014 will speak ... the JW Marriott Hong Kong on Friday, October 10 th ... and the lessons those hold for others. The awards, which recognises ... decade, will be presented at a ceremony in Hong ... the first time the ceremony has come to Asia ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Spectra Automation Introduces RECONN Bioprocess Manager 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... the largest international study to date into the genetic basis ... disease and provide evidence that large-scale genetic studies can assist ... as rheumatoid arthritis. The study, conducted by Dr. Robert ... Institute in the USA and Dr. Yukinori Okada from the ...
... a recent study published in the Neural Regeneration ... Li and team from Zhongshan School of Medicine, Sun ... BACE1, the key enzyme in amyloid beta protein (Aβ) ... construct a short hairpin (shRNA) expression plasmid against the ...
... is in ideal cardiovascular health, according to the new CANHEART ... CMAJ ( Canadian Medical Association Journal ). Cardiovascular ... leading cause of death in Canada. "A large proportion ... trend has not changed in the past decade," says senior ...
Cached Biology News:Rheumatoid arthritis research shows the potential of large-scale genetic studies for drug discovery 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 2Fewer than 1 in 10 Canadians in ideal cardiovascular health 3
... The AccuSpot automates LC microfractionaction, spotting and ... the AccuSpot system, LC eluent can be ... in trace amounts (eg.50nl). Matrix solutions can ... preparation of target plated for MALDI-TOF-MS measurements. ...
Glycerokinase; from Bacillus stearothermophilus...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
...
Biology Products: